ME1 and cancer: It has been previously shown that Nrf2 can redirect glucose and glutamine to anabolic pathways in cancer cells, and Me-1 is implicated in these pathways [60]; however, these results in cancer cells cannot necessarily be safely extrapolated to nontransformed hepatocytes [61].